Some studies have suggested that SUMOylation levels, including SUMO2, may be dysregulated in AD brains (McMillan et al., 2011; Lee L. et al., 2014; Ficulle et al., 2018). This evidence concerns the gene SUMO2 and Alzheimer disease.